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I-Introduction
Malignant blood diseases may be classified:
• According to the clinical course:
• chronic leukemias • acute leukemias • According to the lineage:
• lymphoid lineage: B or T • myeloid lineage:
o myeloproliferative syndromes: quantitative anomalies o myelodysplastic syndromes:
qualitative anomalies o acute myeloid leukemias (or acute non lymphoblastic leukemias ) • According to the primary site:
• leukemia: originates in the bone marrow; flows into the peripheral blood • lymphoma: originates in the lymph nodes; invades bone marrow and blood
The cell Morphology (according to the FAB (FrenchAmerican-British) classification of leukemias), the Immunophenotype and the Cytogenetic findings (MIC) allow a specific classification.
II-Myeloproliferative syndromes
Myeloproliferations: quantitatives anomalies of the myeloid lineage.
II-1. Chronic myeloid leukemia (CML)
• malignant monoclonal process involving a pluripotent hematopoietic progenitor (therefore, most of the lineages are implicated) • splenomegaly, high leukocyte count, basophilia, immature cells in the peripheral blood, low leucocyte alkaline phosphatase, bone marrow expansion with increased neutrophil lineage • prognosis: chronic phase, followed by blast crises, ending in an acute transformation; median survival used to be of 4 yrs before the new treatments
Chromosome anomalies:
• t(9;22)(q34;q11)
• chromosome 22 appears shorter and was called Philadelphia chromosome (noted Ph) • translocates (part of) an oncogene, ABL, sitting usually in 9q34, next to (part of) another oncogene, BCR (breakpoint cluster region), in 22q11 --> production of a hybrid gene 5' BCR-3'ABL • the normal ABL is transcribed into a m-RNA of 6 to 7 kbases, which produces a protein (tyrosine kinase) of 145 kDalton • the hybrid gene BCR-ABL, result of the translocation t(9;22), is transcribed into a m-RNA of 8.5 kb, which produces a protein of 210 kDa with: 1) an increased protein kinase activity 2) an increased half-life, as compared to normal ABL • In a percentage of cases, there is a variant translocation, also implicating a third chromosome (e.g. t(1;9;22)); the implication of chromosome 9 or chromosome 22 may even be hidden (e.g. t(12;22); at times, finally, the karyotype seems normal ("Ph-CML"); however, the gene hybride BCR-ABL is always present (otherwise, it is NOT a CML!) • therefore the translocation t(9;22) is the specific anomaly found in CML however, this anomaly is not pathognomonic, as it may also be found in ALL or in ANLL • additionnal anomalies : most often found at the time of the blast crisis, they may also be present at diagnosis; mainly: +Ph, and/or +8, and/or (17q), and/or +19, and/or -7; clonal evolution II-2. Other myeloproliferative syndromes • Polycytemia vera (PV) : red cell lineage mainly; median survival: 10 to 15 yrs • Idiopathic myelofibrosis (or agnogenic myeloid metaplasia) : splenic metaplasia with progressive myelofibrosis ; survival is very variable (3 to 15 yrs) Chromosome anomalies:
• rare at diagnosis: del(20q), or +8, or +9, or del (13q), or partial trisomy for 1q • frequent during acute transformation:
anomalies are the one found in usual ANLL or in secondary leukemias (see below) • Essential thrombocythemia (ET): megakaryocytic lineage mainly; survival = 10 yrs; chromosome anomalies are rare
III-Myelodysplastic syndromes (MDS)
Dysmyelopoiesis: qualitative anomalies of the myeloid lineage Classified according to the FAB:
• refractory anemia without excess of blasts (RA) • refractory anemia with excess of blasts (RAEB) • refractory anemia with ringed sideroblasts (RARS) • chronic myelomonocytic leukemia (CMML) • Aside : secondary myelodysplasias (see secondary acute leukemias) Chromosome anomalies :
• del(5q) (or -5, of identical signification)
• del(7q) (or -7, equivalent)
• +8
• various structural rearrangements of: 11q, 12p, or chromosome 3
IV-Acute non lymphoblastic leucemias (ANLL)
or acute myeloid leukemias (AML), the term myeloid being a bit confusing
• massive proliferation of myeloid precursors;
• the chromosome anomaly bears a prognostic value 
V-Secondary acute leukemias
• induced leukemias: treatment related (or "therapy related") leukemia (after chemo and/or radiotherapy for a prior cancer), or leukemia after professional exposure to carcinogenetic (genotoxic) chemicals or physical agents • very poor prognosis Chromosome anomalies : frequent, often complex:
• multiple monosomies (hypoploidy)
• del(5q) or -5
• del(7q) or -7
• rearrangements 6p, 12p, 17p, 11q23...
VI-Acute lymphoblastic leukemias (ALL)
• heavy proliferation of B or T lymphoid precursors, • the immunophenotyping (CD, Ig) allows the recognition of the lineage involved in the malignant process, and the degree of maturation of the malignant cell • the morphology differenciates ALL1 and 2 on one hand, and ALL3 with large Burkitt-type cells on the other hand • --> MIC classification (Morphology, Immunophenotype, Cytogenetics) allows to define entities with given prognoses • ALL often occur in childhood Chromosome anomalies, main entities:
• t(4;11)(q21;q23) : immature (CD19+) B-cell; occurs often in childhood, especially very early (congenital leukemia, before 1 yr); very poor prognosis (median survival below 1 yr), the treatment being a bone marrow graft; genes MLL in 11q23 and AF4 in 4q21 • other 11q23 ; MLL and a shared clinical profile • t(9;22)(q34;q11) : B-cell; very poor prognosis; at the molecular level: ABL and BCR ; P210 in half cases, P190 in the other half, as is in ANLL with t(9;22) • t(12;21)(p12;q22) : CD10+ B ALL in childhood; genes ETV6 and AML1 • t(8;14)(q24;q32) and variants t(2;8)(p12;q24) and t(8;22)(q24;q11): t(8;14) being the most frequent; quasi pathognomonic of L3-ALL and Burkitt lymphoma (mature B malignant cell); the prognosis was poor until recently, where new treatments are accompanied with better outcome; MYC in 8q24; immunoglobulin heavychains (IgH) in 14q32, or light-chains K (Ig K) in 2p12 and L (IgL) in 22q11; these translocations set the oncogene under the regulation of immunoglobulin transcription stimulating sequences (active in the Blineage), leading to overexpression • t(11;14)(p13;q11), t(8;14)(q24;q11) and t(10;14)(q24;q11) : T-cell leukemia; T-cell receptor (TCR D et A) belonging to the immunoglobulin superfamilly in 14q11; RBTN2 in 11p13, HOX11 in 10q24, and, obviously, MYC in 8q24; comparable to the above, with here an oncogene under the regulation of the T-cell receptor transcription stimulating sequences (active in the T-lineage), leading to overexpression • del(6q), 9p rearrangements, 12p rearrangements, quasi-haploidy, hyperploidy (hyperploidy _ 50 ; hyperploidy > 50, they are of good prognosis), are not rare ALL
VII-Non hodgkin's lymphomas
• classified into numerous categories (see non Hodgkin lymphomas classification according to the cell and tissue morphology, and correlated with the prognosis (low to high grades)
• chronic lymphoid leukemia is considered as a leukemia by the haematologists and as a low grade lymphoma by the pathologists • Chronic lymphoid leukemia (CLL): often a very slow process (10-15 yrs), at times very fast Chromosome anomalies:
• +12, 14q32 rearrangements , del(6q) , 13q rearrangements, del(11q), +3, +18 , non identifiable markers; often as associated anomalies • Non Hodgkin's lymphomas (NHL) chromosome anomalies:
• t(14;18)(q32;q21) : typically, found in small cleaved B-cell lymphomas; BCL2 (B cell lymphoma 2) in 18q21, a gene of the BCL2/BAX familly, implicated in the abrogation/induction of apoptosis ("programmed cell death"), immunoglobulin heavy-chain (IgH) in 14q32; BCL2 (protein of the inner membrane of the mitochondria), in case of a translocation t(14;18), is set under the regulation of immunoglobulin transcription stimulating sequences (active in the B-lineage), and overexpressed (as above) • other 14q32 rearrangements: of which is the t(11;14)(q13;q32) often seen in mantle cell lymphomas • 14q11 rearrangements: T-cell lymphomas;
TCR A et D (T-cell receptor) in 14q11, and, at the breakpoint on the partner chromosome, an 
